IMDXHealthcare · Diagnostics & ResearchIMDX Stock Forecast: Insight Molecular Diagnostics, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Insight Molecular Diagnostics, Inc. hold a median 12-month price target of $9 — +78.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 1 Aug 2026 — in the lower half.
IMDX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Insight Molecular Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Insight Molecular Diagnostics, Inc. — and when they’d sell — is the membership.
IMDX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IMDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +78.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Feb 2026 | Lake Street | Maintains | Buy | $8.00 → $12 |
| 11 Nov 2025 | Needham | Maintains | Buy | — |
| 18 Aug 2025 | Needham | Reiterates | Buy | — |
| 21 May 2025 | Lake Street | Maintains | Buy | — |
| 13 May 2025 | Needham | Reiterates | Buy | — |
| 8 Apr 2025 | Needham | Reiterates | Buy | — |
| 28 Mar 2025 | Lake Street | Initiates | Buy | — |
| 26 Mar 2025 | Stephens & Co. | Reiterates | Equal-Weight | — |
| 25 Mar 2025 | Needham | Reiterates | Buy | — |
| 25 Mar 2025 | Stephens & Co. | Reiterates | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
IMDX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Insight Molecular Diagnostics, Inc. (IMDX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −2.8×
- Price / sales
- 77.0×
- Price / book
- −15.1×
- EV / EBITDA
- −3.8×
Cheaper than 86% of US stocks
Cheaper than 4% of US stocks
Cheaper than 98% of US stocks
Cheaper than 77% of US stocks
- Revenue growth (YoY)
- −98.5%
- Earnings growth (YoY)
- —
- Gross margin
- 46.9%
- Operating margin
- −32275.0%
- Net margin
- 56.7%
Higher than 1% of US stocks
Higher than 60% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
- Return on equity
- 159.6%
- Return on assets
- −43.4%
- Dividend yield
- —
Higher than 97% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
IMDX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMDX appears on the weeks it earns a place.
Frequently asked questions about IMDX stock
What is the IMDX stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Insight Molecular Diagnostics, Inc. have a median 12-month price target of $9, with estimates ranging from $4 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IMDX stock a buy right now?
Of the 4 analysts covering Insight Molecular Diagnostics, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Insight Molecular Diagnostics, Inc. 49 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IMDX?
As at 1 Aug 2026, Insight Molecular Diagnostics, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
Will IMDX stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +78.9% from the last close, and Ticker Nerd's factor model ranks Insight Molecular Diagnostics, Inc. 49 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IMDX stock forecast for 2030?
No analyst covering Insight Molecular Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $12 over the next 12 months.
How has IMDX stock performed over the past year?
Insight Molecular Diagnostics, Inc. returned +96.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Insight Molecular Diagnostics, Inc. do?
Insight Molecular Diagnostics Inc. is a precision diagnostics company specializing in the development and commercialization of advanced molecular diagnostic tests for both clinical and research applications.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics Inc. is a precision diagnostics company specializing in the development and commercialization of advanced molecular diagnostic tests for both clinical and research applications. With a core focus on transplant medicine and oncology, the company’s product portfolio includes laboratory-developed tests, kitted research-use-only assays, and kitted clinical tests targeting key unmet needs in patient care. Notable offerings are its VitaGraft Kidney and VitaGraft Liver tests, which use blood-based detection of donor-derived cell-free DNA to monitor for organ transplant rejection, and the GraftAssure suite, which leverages droplet digital PCR technology for highly sensitive transplant monitoring. In the oncology space, Insight Molecular Diagnostics is developing DetermaCNI—a blood-based assay to detect early progression after one cycle of cancer treatment—and DetermaIO, a test predicting response to immunotherapies by assessing the tumor microenvironment. The company also engages in biomarker discovery, assay development, and supports clinical trials for pharmaceutical partners. Through collaboration with industry leaders such as Bio-Rad Laboratories, Insight Molecular Diagnostics contributes to both research and in-vitro diagnostic advancements. Founded in 2009 and now headquartered in Nashville, Insight Molecular Diagnostics plays a significant role in improving patient outcomes across the healthcare landscape by enabling personalized and real-time intervention through precision diagnostics.
CEO Mr. Joshua Riggs · 55 employees · United States · https://www.imdxinc.com